Purpose {#sec1}
=======

Cervical cancer is the fourth most common cancer in women worldwide \[[@cit0001]\]. In 2012, there were an estimated 266,000 deaths from cervical cancer worldwide, accounting for 7.5% of all female cancer deaths \[[@cit0002]\]. A large majority (around 85%) of the global burden occurs in the less developed regions, where it accounts for almost 12% of all female cancers. Almost nine out of ten (87%) cervical cancer deaths occur in the less developed regions \[[@cit0002]\]. Except for the very early cases, radiation therapy is the major curative treatment option for this disease. Brachytherapy plays an anchor role in management of cervical cancer and forms an integral part of radiation therapy. Intracavitary brachytherapy remains the most commonly practiced form of brachytherapy for cervical cancer \[[@cit0003]\].

While various recommendations are available for intracavitary insertion techniques, dosage schedule, dose prescriptions, and reporting of the procedure, to date, no guideline is available regarding the selection of the applicator type and optimization technique. A choice of applicator is rather arbitrary \[[@cit0004]\], and depends on availability, patients' pelvic geometry as well as extent of disease. However, since the dose distribution in brachytherapy follows inverse square law, different patterns of dose distribution were generated with different applicator systems, some of these may help to achieve higher therapeutic ratio by sparing the organs at risk and, at the same time, covering the target in a more satisfactory manner than the other.

Objectives of our study {#sec1.1}
-----------------------

The recommended dose volume objective for clinical target volume (CTV) is to deliver a minimum of 100% of prescribed dose to 90% volume (D~90~) of CTV. Whereas, the dose volume constraints recommended for different organs at risk (OARs) are: (a) less than 75 Gy two-gray equivalent dose (EQD~2~) to 2 cc (D~2cc~) volume of contoured rectum and sigmoid colon, and (b) less than 90 Gy EQD~2~ to 2 cc volume of urinary bladder \[[@cit0005], [@cit0006], [@cit0007]\]. Different high-dose-rate (HDR) brachytherapy fractionation protocols are currently practiced after external beam radiotherapy (EBRT). To engender total EQD~2~ to the contoured volumes, different fractionation protocols will have different permissible D~2cc~ for OARs per fraction of brachytherapy. Our study aims to compare dose volume and dose point parameters using three-dimensional (3D) treatment planning for two different applicator systems and three forward planning-optimization techniques in same patients, to find out the best suitable applicator-optimization combination to fulfill dose volume objectives. The two applicator systems are tandem-ring and Fletcher-style tandem ovoid applicators. The three optimization techniques are 'no optimization', a term used in our treatment planning software, which sets equal dwell weight/times of all dwell positions; 'manual optimization' setting weight of ovoid/ ring dwell positions to 0.33 of those in tandem, as proposed by a study by Obed *et al.* \[[@cit0008]\]; and 'graphical' to drag the isodose lines to conform to the contoured CTV and sparing the OARs.

Material and methods {#sec2}
====================

Patients selection {#sec2.1}
------------------

At our institution, we treat nearly 300 newly-diagnosed cases of cervical cancer every year. Among them, 22 patients ([Table 1](#t0001){ref-type="table"}) suffering from locally advanced disease (stage IIA-IIIB), squamous cell carcinoma in histology with good performance status (ECOG 0-2) and no other significant co-morbidities (which might alter treatment outcomes) were selected for this study. Patients with gross residual tumor after EBRT or having distorted anatomy of vaginal fornices were excluded from the study.

###### 

Patient characteristics according to stage

  Stage of the disease   Number of patients   \%
  ---------------------- -------------------- ------
  IIA                    5                    22.7
  IIB                    11                   50
  IIIB                   6                    27.3

External beam radiotherapy technique {#sec2.2}
------------------------------------

All patients received a dose of 50 Gy to the whole pelvis in conventional fractionation with four field box technique prior to brachytherapy, along with concurrent chemotherapy of cisplatin 40 mg/m^2^ given weekly. In patients with extensive parametrial disease involvement, a further 10 Gy parametrial boost in conventional fractionation was delivered by parallel opposed antero-posterior beams. However, in these patients, brachytherapy insertions were intertwined between the parametrial boost fractions to keep the total duration of treatment within eight weeks. When interdigitating brachytherapy, caution was taken not to administer weekly chemotherapy on a brachytherapy day, but to deliver rather on an EBRT day to avoid the possibility of increased adverse effects due to normal-tissue sensitization.

Brachytherapy insertion {#sec2.3}
-----------------------

Oral anxiolytic and stool softener were given to the patient the night before the procedure. Intracavitary insertion was done under intravenous sedation by an experienced radiation oncologist. Tandem-ring and the Fletcher-style tandem ovoid applicators (Nucletron, an Elekta company, Stockholm, Sweden) were used for same patients in two different insertions. For each patient included in this study, the type of applicators and sequence of insertion were randomly assigned using a blind envelope method. Patients were randomly assigned to receive first insertion using either ring or Fletcher applicator; the other type being used for the second insertion. This random assignment of the insertion sequence ensured that changes in local anatomy due to progressive tumor shrinkage, as well as general patient condition at the time of insertion would be balanced between uses of two applicator systems. To engender comparability, the selected basic parameters for insertion according to patient's utero-vaginal anatomy, e.g. the intra-uterine tandem length, angulation, and lateral separation were kept as similar as feasible for both applicators. Ovoid separation or ring diameter used were both the same, as permitting by patient's anatomy. All patients underwent a computerized tomographic (CT) scan (3 mm slice) using Philips Brilliance CT simulator (Philips Healthcare, Inc., Andover, MA, USA) after every insertion with the applicators in position.

Brachytherapy contouring {#sec2.4}
------------------------

Oncentra^®^Brachy version 4.5.2 treatment planning system (Nucletron, an Elekta company, Stockholm, Sweden) was used for 3D treatment planning. Whole of the cervix with any parametrial extension was contoured following the guideline of American Brachytherapy Society (ABS) Cervical Cancer Brachytherapy Task group \[[@cit0006]\], extending superiorly up to the location where the uterus began to enlarge. If these could not be identified, a height of 3 cm was contoured for the cervix. A portion of tandem inside the cervix was included in the contoured clinical target volume (CTV). The whole of urinary bladder inclusive of the Foley's catheter bulb, whole of rectum, and sigmoid colon were contoured as organs at risk. ICRU reference points, namely point A and B on right and left sides, bladder, and rectal points were identified.

Optimization techniques {#sec2.5}
-----------------------

After catheter reconstruction, activation of dwell positions was done in similar fashion between two applicator systems to ensure comparability. Three types of optimization techniques, as described earlier, were carried out after each of two insertions by an experienced medical physicist and thus, six plans were created and saved for each patient for dosimetric comparison. All plans were normalized to left sided point A to ensure uniformity prior to comparison, while normalization was ascertained again after optimization. Three other optimization techniques, namely IPSA (inverse planning simulated annealing), HIPO (hybrid inverse planning optimization), and geometric optimization were not used as the first two are not licensed to our planning system and the last was not applicable. The usual practice at our department is prescription of 8 Gy to the normalized point A. A dose of 86 Gy EQD~2~ (α/β = 10) was delivered to point A. Prescription was reviewed by treating oncologist and radiation safety was checked by the radiation safety officer.

The procedure of brachytherapy insertion includes the use of intravenous sedation, CT imaging, and prescription of dose to point A, which were all in accordance with 'modifications from American Brachytherapy Society (ABS) 2012 consensus guidelines for practice in resource-limited settings (RLSs)' \[[@cit0009]\]. Treatment was effected using ^192^Ir source in HDR-microselectron brachytherapy set-up (Nucletron, an Elekta company, Stockholm, Sweden).

Documentation {#sec2.6}
-------------

All dose volume parameters D~90~, D~100~, V~100~ (volume covered by 100% isodose), V~150~ (volume covered by 150% isodose), and V~200~ (volume covered by 200% isodose) for CTV and D~0.1cc~ (dose to 0.1 cc volume), D~1cc~ (dose to 1 cc volume), D~2cc~, V~20~ (volume covered by 20% isodose), V~50~ (volume covered by 50% isodose), V~85~ (volume covered by 85% isodose), and V~95~ (volume covered by 95% isodose) for rectum, sigmoid colon, and urinary bladder were documented. Dose point parameters like dose to bladder and rectal point, contralateral un-normalized point A and bilateral point B were noted. Additionally, width (the maximum and at the level of point A) and maximum height of volume enclosed by 100% isodose curve, total reference air kerma (TRAK) at 1m, and treatment time were recorded.

Statistical analysis {#sec2.7}
--------------------

Online calculator available at <http://www.graphpad.com> was used for data analysis. Paired *t*-test was used to compare dose-volume, dose-point, and other parameters between two applicator systems using each of three optimization techniques. EQD~2~ calculations had been done using LQ (linear quadratic) spreadsheet available at American Brachytherapy Society's <http://www.americanbrachytherapy.org/guidelines/LQ_spreadsheet.xls> website.

Discussion {#sec3}
==========

Treatment modalities {#sec3.1}
--------------------

American Brachytherapy Society (ABS) recommends that EBRT and brachytherapy should be completed in less than 8 weeks with interdigitating these if needed for better local tumor control and survival. When interdigitated, chemotherapy should be administered on an EBRT day and not on a brachytherapy day to avoid potential for increased complications \[[@cit0005]\]. Superior dosimetric coverage of parametrium has been reported after addition of intensity modulated radiotherapy (IMRT) \[[@cit0010]\] or interstitial brachytherapy (ISBT) \[[@cit0011]\] with intracavitary brachytherapy.

Imaging {#sec3.2}
-------

The Groupe Européen de Curiethérapie -- European Society for Radiotherapy & Oncology (GEC-ESTRO) recommends the use of magnetic resonance imaging (MRI) with T2w pulse sequences both at the time of diagnosis and brachytherapy \[[@cit0012]\], since there is significant reductions in normal tissue toxicity, improvements in local control, and overall survival after MRI-guided adaptive brachytherapy \[[@cit0013]\]. Although magnetic resonance imaging (MRI) is superior to CT for the differentiation of gross tumor volume (GTV) and parametrial disease \[[@cit0014]\], CT and MRI provide basically similar quality for discrimination of bladder, rectum, sigmoid, bowel, and vagina \[[@cit0007]\]. In limited resource setting, MRI based preplanning at the first brachytherapy application and consecutive CT/MRI data fusion has been demonstrated to be safe and feasible by Dolezel *et al.* \[[@cit0015], [@cit0016]\]. In absence of MRI, CT scans alone when used for brachytherapy planning can ensure organs at risk (OAR) doses to be kept within acceptable limits. However, CT based target volumes have been overestimated as compared to MRI volumes \[[@cit0015], [@cit0017]\].

Contouring {#sec3.3}
----------

For locally advanced disease, point A based prescription can result in under dosage or geographic misses as has been documented on CT images \[[@cit0015], [@cit0018], [@cit0019]\]. Image-guided brachytherapy with 3D volume contouring and assessment of dose volume parameters should be done to ensure good coverage to target and sparing of organs at risk. For institutions that utilize CT, the width of the cervix and any parametrial extension should be contoured as CTV-CT \[[@cit0006]\]. The superior border of the cervix should extend at the location where the uterus begins to enlarge or at least 1 cm above either the uterine vessels identified by IV contrast. If these cannot be identified, a height of 3 cm should be contoured for the cervix \[[@cit0006]\]. When reporting DVH (dose volume histogram) parameters, it should be always mentioned if the applicator is included in the contoured CTV or not \[[@cit0007]\]. For organ wall volumes up to 2-3 cm^3^, organ and organ wall contouring lead to almost identical numerical results \[[@cit0020]\], which allows for organ contouring only. If larger organ wall volumes are considered, organ wall contouring has to be performed \[[@cit0007]\].

Dose prescription and optimization {#sec3.4}
----------------------------------

Dosimetry should be performed every time applicators are inserted to assess dose to the target volumes as well as the normal tissues, even if fixed geometry applicators are used \[[@cit0006]\]. Dose has been prescribed historically as milligram per hour of radium or total reference air kerma (TRAK), and is currently mainly prescribed to specific well-defined points (e.g. point A) or volumes \[[@cit0006]\]. Optimization in the 2000 ABS Guidelines \[[@cit0005]\] refers to setting lateral dose points adjacent to the applicator, based on radiographic localization. With 3D-imaging, optimization refers to starting with a customary loading of the full length of the tandem and the vaginal applicator (ovoids, ring, or cylinder), then modifying the dwell positions to reduce the dose to the OAR and ensure maximal tumor coverage. American Brachytherapy Society recommends that, although point A dose should be recorded; the priority is to administer planned EQD~2~ to D~90~ (volume covered by 90% of the prescribed dose) of contoured clinical target volume (CTV) \[[@cit0005]\]. If prescription is based on a target volume and not on point A, it is still possible to normalize to point A by changing the normalization value until the prescribed isodose reaches a certain dimension \[[@cit0007]\].

Assessment of dose volume parameters {#sec3.5}
------------------------------------

Cumulative dose volume histograms (DVH) are recommended for evaluation of the complex dose heterogeneity. DVH parameters for target volume are the minimum dose delivered to 90% (D~90~) and 100% (D~100~). Due to the steep dose gradient, small spikes in the contour cause large deviations in D~100~. D~90~ is less sensitive to these influences, and is therefore considered to be a more 'stable' parameter \[[@cit0007]\]. Volume enclosed by 150% (V~150~) or 200% (V~200~) of the prescribed dose is recommended for overall assessment of high-dose regions. Volume enclosed by 100% of prescribed dose (V~100~) is recommended for quality assessment, only within a given treatment schedule. For OAR, the minimum dose to the most irradiated tissue volume recommended for reporting are 0.1, 1, and 2 cm^3^; optionally 5 and 10 cm^3^ \[[@cit0007]\].

Optimum organ at risk volume {#sec3.6}
----------------------------

Optimum bladder volume is essential to minimize dose to pelvic organs at risk. A study by Siavashpour \[[@cit0021]\] revealed that choosing a bladder with a volume of about 70 cm^3^ or less was recommended when taking into account the high-dose volume parameters for bladder, rectum, and sigmoid. Another study by Patra *et al.* \[[@cit0022]\] revealed that with distension of bladder, mean bladder dose and small volume dose parameters (0.1 cc, 1 cc, and 2 cc) of small intestine decreases. However, there is no significant change in these parameters of bladder, rectum, and sigmoid colon.

Recommended prescribed dose {#sec3.7}
---------------------------

D~90~ of contoured target volume should be equal to 100% of prescription dose. American Brachytherapy Society recommends EQD~2~ of ≥ 80 Gy for patients with either a complete or a partial response with residual disease less than 4 cm, and an EQD~2~ of 85-90 Gy for non-responders or those with tumors larger than 4 cm at the time of brachytherapy \[[@cit0005]\]. D~2cc~ of rectum or sigmoid less than 75 Gy and D~2cc~ of urinary bladder less than 95 Gy have been reported \[[@cit0006]\]. ABS recommends EQD~2~ limit for the rectum and sigmoid as 70-75 Gy and for the bladder as 90 Gy \[[@cit0005]\]. European study on MRI-guided brachytherapy in locally advanced cervical cancer (EMBRACE) \[[@cit0023]\] and Cancer Care Ontario (CCO) \[[@cit0024]\] also set same doses for organs at risk.

Uncertainties {#sec3.8}
-------------

Multiple applications can lead to a variation in the spatial position of applicators in relation to the pelvic organs, bones, and the organs at risk, mainly attributed to patient movement and tumor regression during the interval between multiple fractions \[[@cit0015]\]. These have been reported in terms of changes in the uterine axis, uterine length, colpostat separation, and vaginal packing or slippage of tandem, filling state of bladder and rectum etc. \[[@cit0015], [@cit0025]\]. Thus, for accurate assessment of dose volume parameters, imaging after each insertion of brachytherapy is preferable. However, intra-fraction errors due to bowel movements or movement of patient cannot be ruled out. GEC-ESTRO (The Groupe Européen de Curiethérapie -- European Society for Radiotherapy and Oncology) made assumptions of full dose of external beam therapy in the volume of interest, identical location during fractionated brachytherapy, and contiguous volumes \[[@cit0007]\] to ignore these uncertainties.

Comparison of two applicator systems {#sec3.9}
------------------------------------

Both ring and Fletcher applicators are based on the Manchester system, but their geometry is quite different (see [Figure 1](#f0001){ref-type="fig"}). Fletcher applicator system consists of three applicators: the intrauterine tandem, activation of source dwell positions along, which generates the dose longitudinally, and the two angulated lateral ovoids responsible for widening the dose laterally to point A and also antero-posteriorly. It has flexible geometry as the separation and the relative longitudinal position of the applicators can be adjusted. Although the three applicators are fixed by screws outside vagina, the positioning of the ovoids within the fornix may be asymmetric, as it largely depends on the shape and symmetry of the vaginal fornix. The assembled Fletcher apparatus exhibits a wider distribution at the level of the ovoids as well as thicker anterior/posterior distribution. The ring applicator system is a fixed-geometry two-applicator system, where the tandem and the single ring applicator can be fixed only at a particular slot inside the vagina, and operating oncologist is constrained to select one of the ring sizes available in his institution. Patients with shallow vaginal fornices or those having partially fixed utero-vaginal anatomy not matching the geometry of the available ring applicators, cause difficulty in proper placement of the applicators. However, if patient's anatomy is symmetric and favorable, some oncologists find insertion of ring applicator easier than Fletcher applicator.

![Figure showing **(A)** intracavitary brachytherapy applicators: Fletcher applicator on the left and ring applicator on the right, **(B)** diagram showing comparative geometry of the two applicators, **(C)** assembled applicators -- ring applicator above and Fletcher applicator below. Fletcher applicator is a flexible geometry three-applicator system, the positioning which may be asymmetric depending on the shape and symmetry of the vaginal fornix. The assembled Fletcher apparatus exhibits a wider distribution at the level of the ovoids as well as thicker anterior-posterior distribution. Ring applicator is a fixed-geometry two-applicator system. Patients with shallow vaginal fornices or partially fixed utero-vaginal anatomy not matching the geometry of the ring applicator cause difficulty in proper placement of the applicators](JCB-9-30804-g001){#f0001}

Trials comparing two applicator systems {#sec3.10}
---------------------------------------

Dose distributions for Fletcher-style tandem ovoid (TO) and tandem-ring (TR) applicators have been compared at ICRU (International Commission on Radiation Units and Measurements) point A, bladder and rectal points using Abacus software in a study by Rehman *et al.* They observed that dose at point A was significantly higher and doses to bladder and rectal point were smaller (statistically insignificant) for the Fletcher applicators. They concluded that Fletcher applicator achieved a better dose distribution, thus predicting a better treatment outcome \[[@cit0026]\]. In a study by Levin *et al.* \[[@cit0027]\], dosimetric comparisons of these two applicators were investigated using CT-guided volume determination. The authors showed that even though the optimization point doses were similar between the two applicators, tandem-ovoid applicator clearly exhibited a larger isodose volume in comparison to ring applicator. A study conducted at University of Mississippi by Ma *et al.* \[[@cit0028]\] compared the short-term toxicity and dosimetry of these applicators. They observed that although the rectal D~2cc~ was statistically similar between TO and TR, the mean rectal dose in TR was lower. V~95~, V~85~, V~50~, and V~20~ were all significantly higher for TO than for TR (*p* \< 0.018). Despite the larger isodose volume seen in TO, the percent of the CTV that received 100% of the prescription dose (CTV~100%~) and the percent of prescription dose covering 90% of the CTV (D~90~) were not statistically different. This study had certain limitations. In order to modify the isodose curve to bring OAR D~2cc~ under GEC-ESTRO recommendations, optimization was achieved by adjusting the radioactive source loading patterns, dwell positions, and dwell times. Thus, the difference in dose distribution may had been offset by intentional optimization to spare organs at risk. For this reason, both sets of patients had similar short term toxicities. Furthermore, CTV was contoured retrospectively, and the two types of applicators were inserted by two surgeons in different patients.

Trials comparing different loading patterns {#sec3.11}
-------------------------------------------

An orthogonal imaging based study in Nigeria by Obed *et al.* \[[@cit0008]\] compared two loading patterns using only ring applicator system. They observed that the means of all evaluated dose parameters decreased when tandem-ring dwell time ratio 1 : 1 was modified to other dwell weightings, 1 : 1 -- 3 : 1. These reductions were 13.43% for ICRU volume in cm^3^ (ICRU~H~ × ICRU~W~ × ICRU~T~), 9.83% for rectal dose, 6.68% for point B dose, 6.08% for treatment time, 5.90% for TRAK, and 1.08% for bladder dose \[[@cit0008]\]. No study to date has compared the effects of different optimization techniques or loading patterns along with different applicator systems in same patients.

Achieved results from our study and their implications {#sec3.12}
------------------------------------------------------

Dose distribution from Fletcher applicator is both wider side to side and thicker antero-posteriorly even if the lateral separation of ovoids are identical with ring diameter and source loading patterns are planned in a similar way (see [Figure 2](#f0002){ref-type="fig"}). Unless graphical optimization is performed, maximum width and thickness of 100% isodose, TRAK at 1m ([Table 3](#t0003){ref-type="table"}), V~100~, V~150~, V~200~, and D~90~, D~100~ of CTV ([Table 2](#t0002){ref-type="table"}) are statistically significantly (*p* \< 0.0001) high with Fletcher applicator. This difference is nullified with graphical optimization. However, even if this is done, dose to un-normalized point A (on patient's right side), both point B ([Table 3](#t0003){ref-type="table"}), minimum dose to CTV ([Table 2](#t0002){ref-type="table"}), and treatment time remain significantly higher with the use of Fletcher applicator. Recorded maximum dose to CTV is very high and the same for both applicators, and in all plans as it is located in the immediate vicinity of the applicators. Maximum height of 100% isodose curve is not statistically different due to identical loading patterns ([Table 3](#t0003){ref-type="table"}).

###### 

Comparative assessment of dose volume data from median values of all patients

###### 

1\. Dose volume data for contoured CTV

                     FNO    RNO   *p*-value   FMO   RMO   *p*-value   FGO   RGO   *p*-value                                
  ------------------ ------ ----- ----------- ----- ----- ----------- ----- ----- ----------- ---- ----- ----- ----- ----- ------
  D~90~ (cGy)        1166   169   716         148   ES    990         152   646   132         ES   807   139   802   121   0.89
  D~100~ (cGy)       723    125   488         107   ES    613         113   456   90          ES   495   84    513   79    0.46
  V~100~ (%)         91     3.0   80          4.1   ES    93          2.1   74    4.4         ES   90    3.1   88    4.5   0.13
  V~150~ (%)         88     3.4   43          5.2   ES    74          9.8   45    7.9         ES   56    15    56    13    1.0
  V~200~ (%)         62     8.3   24          6.9   ES    51          7.1   24    5.3         ES   32    9.8   34    13    0.57
  Minimum dose (%)   98     16    59          15    ES    86          14    57    11          ES   80    12    88    12    0.03
  Maximum dose (%)   800    0     800         0     --    800         0     800   0           --   800   0     800   0     --
  Median dose (%)    253    16    142         15    ES    223         21    134   17          ES   142   21    232   20    ES
  Average dose (%)   314    6.3   194         5.7   ES    291         19    185   16          ES   194   23    311   22    ES

CTV -- clinical target volume, D~90~ (cGy), D~100~ (cGy) -- percent of the prescription dose covering 90%, 100% of the CTV, V~100~ (%), V~150~ (%), V~200~ (%) -- volume of the anatomic volume receiving 100%, 150%, 200% of the prescribed dose p \< 0.05 -- statistically significant, ES -- extremely statistically significant (p \< 0.0001), SD -- standard deviation

###### 

2\. Dose volume data for contoured rectum

                     FNO    RNO   *p*-value   FMO   RMO   *p*-value   FGO   RGO    *p*-value                                     
  ------------------ ------ ----- ----------- ----- ----- ----------- ----- ------ ----------- ---- ------ ------- ------ ------ --------
  D~0.1cc~ (cGy)     1020   33    559         30    ES    1008        158   519    141         ES   738    110     634    72     0.0006
  D~1cc~ (cGy)       925    59    463         142   ES    861         172   396    131         ES   632    83      520    54     ES
  D~2cc~ (cGy)       853    73    421         80    ES    782         141   358    130         ES   594    80      472    54     ES
  V~20~ (%)          100    4.7   90          4.1   ES    97          3.3   83     5.2         ES   93     5.0     97     6.2    0.02
  V~50~ (%)          44     6.9   9           2.3   ES    31          9.3   18     3.3         ES   20     13.4    15     4.7    0.11
  V~85~ (%)          11     1.4   0           0     --    6           1.9   0.03   0.00        ES   0.7    0.05    0.1    0.02   NA
  V~95~ (%)          6      0.7   0           0     --    3           0.8   0      0           --   0.08   0.002   0.01   0.00   NA
  Minimum dose (%)   30     5.6   18          4.3   ES    23          4.9   16     5.4         ES   25     6.1     28     7.7    0.13
  Maximum dose (%)   144    6.3   80          8.3   ES    123         20    79     13          ES   124    25      120    28     0.61
  Median dose (%)    60     2.1   35          3.8   ES    46          2.1   30     2.3         ES   55     12      51     14     0.31
  Average dose (%)   65     1.7   37          1.8   ES    51          3.5   32     8.8         ES   59     13      55     14     0.31

D~0.1cc~ (cGy), D~1cc~ (cGy), D~2cc~ (cGy) -- minimum dose to the most exposed 0.1 cm^3^, 1 cm^3^, 2 cm^3^, V~20~ (%), V~50~ (%), V~85~ (%), V~95~ (%) -- volume of the anatomic volume receiving 20%, 50%, 85%, 95% of the prescribed dose

p \< 0.05 -- statistically significant, ES -- extremely statistically significant (p \< 0.0001), SD -- standard deviation

###### 

3\. Dose volume data for contoured sigmoid colon

                     FNO   RNO    *p*-value   FMO   RMO     *p*-value   FGO    RGO   *p*-value                                       
  ------------------ ----- ------ ----------- ----- ------- ----------- ------ ----- ----------- ---- ------ ------ ------- -------- ----
  D~0.1cc~ (cGy)     408   138    368         103   0.28    675         199    343   92          ES   616    76     383     120      ES
  D~1cc~ (cGy)       298   89     338         101   0.17    440         104    254   80          ES   413    24     284     91       ES
  D~2cc~ (cGy)       356   56     277         90    0.001   341         62     207   62          ES   321    30     234     60       ES
  V~20~ (%)          94    8.5    48          14    ES      90          13     39    11          ES   91     12.7   48      14       ES
  V~50~ (%)          28    8      8.1         2.2   ES      29          9.2    4.5   1.2         ES   20     14.7   6.8     1.9      ES
  V~85~ (%)          3.2   0.9    0           0     --      4.3         1.1    0     0           --   1.05   0.2    0.005   0.0001   ES
  V~95~ (%)          1.0   0.03   0           0     --      2.4         0.6    0     0           --   0.25   0.07   0       0        --
  Minimum dose (%)   28    5.8    16          3.4   ES      26          6.04   14    4           ES   23     1.3    16      4.5      ES
  Maximum dose (%)   93    19.5   50          15    ES      101         29     47    14          ES   94     16.9   53      13       ES
  Median dose (%)    46    11.8   26          7.2   ES      42          12     26    8           ES   37     4.2    27      7.6      ES
  Average dose (%)   47    12.3   27          8     ES      46          13     25    9           ES   41     4.2    28      8.2      ES

D~0.1cc~ (cGy), D~1cc~ (cGy), D~2cc~ (cGy) -- minimum dose to the most exposed 0.1 cm^3^, 1 cm^3^, 2 cm^3^ volume, V~20~ (%), V~50~ (%), V~85~ (%), V~95~ (%) -- volume receiving 20%, 50%, 85%, 95% of the prescribed dose, p \< 0.05 -- statistically significant, ES -- extremely statistically significant (p \< 0.0001), SD -- standard deviation

###### 

4\. Dose volume data for contoured urinary bladder

                     FNO    RNO   *p*-value   FMO    RMO   *p*-value   FGO    RGO   *p*-value                                     
  ------------------ ------ ----- ----------- ------ ----- ----------- ------ ----- ----------- ------- ------ ----- ----- ------ -------
  D~0.1cc~ (cGy)     1335   111   770         130    ES    1138        180    870   164         ES      1290   185   792   180    ES
  D~1cc~ (cGy)       1164   47    580         44     ES    980         100    610   89          ES      1031   150   645   166    ES
  D~2cc~ (cGy)       1077   51    539         41     ES    911         28.6   549   25          ES      921    110   607   125    ES
  V~20~ (%)          93     3.7   80          8.7    ES    79          10.5   70    7           0.001   70     8.8   87    6.7    ES
  V~50~ (%)          34     10    13          6.3    ES    24          5.6    10    2.3         ES      17     4.3   22    6.2    0.03
  V~85~ (%)          11     3.3   0.35        0.09   ES    6           1.4    0.5   0.1         ES      6      1.8   0.6   0.01   ES
  V~95~ (%)          7      1.5   0.12        0.03   ES    4           0.7    0.3   0.09        ES      4      1.2   0.1   0.00   ES
  Minimum dose (%)   20     5     14          4.2    ES    16          3.6    13    2.5         0.002   20     5.8   22    6.2    0.275
  Maximum dose (%)   198    50    120         47     ES    176         49     139   44          0.012   164    48    173   46     0.53
  Median dose (%)    55     3.7   36          2.7    ES    43          4.2    32    8.4         ES      56     10    56    13     1.0
  Average dose (%)   63     2.8   39          2.9    ES    50          2.8    35    2.3         ES      62     9.1   61    12     0.76

D~0.1cc~ (cGy), D~1cc~ (cGy), D~2cc~ (cGy) -- minimum dose to the most exposed 0.1 cm^3^, 1 cm^3^, 2 cm^3^ volume, V~20~ (%), V~50~ (%), V~85~ (%), V~95~ (%) -- volume receiving 20%, 50%, 85%, 95% of the prescribed dose

FNO -- Fletcher style tandem ovoid applicator with no optimization, RNO -- ring applicator with no optimization, FMO -- Fletcher style tandem ovoid applicator with manual optimization, RMO -- ring applicator with manual optimization, FGO -- Fletcher style tandem ovoid applicator with graphical optimization, RGO -- ring applicator with graphical optimization, p \< 0.05 -- statistically significant, ES -- extremely statistically significant (p \< 0.0001), SD -- standard deviation

###### 

Comparative assessment of dose point and other data (TRAK per fraction at 1m, dimensions of 100% isodose, and treatment time) from median values of all patients

###### 

1\. Dose at ICRU points

                              FNO   RNO   *p*-value   FMO   RMO    *p*-value   FGO    RGO   *p*-value                                   
  --------------------------- ----- ----- ----------- ----- ------ ----------- ------ ----- ----------- ------ ----- ------- ---- ----- ------
  Dose to right point A (%)   123   23    74          2.8   ES     100         10     67    5.7         ES     115   26.16   75   4.2   ES
  Rectal point dose (%)       91    2.1   60          28    ES     66          7.07   42    13          ES     77    19.09   59   35    0.04
  Bladder point dose (%)      74    18    57          9.9   0.12   58          15     50    2.8         0.41   64    16      57   9.9   0.41
  Point B (R)                 31    5.6   19          5.6   ES     27          5.6    18    5.6         ES     25    5.5     20   5.5   ES
  Point B (L)                 26    1.4   22          1.5   ES     24          1.4    21    1.4         ES     24    1.43    20   1.4   ES

###### 

2\. Measurement of 100% isodose curve

                           FNO   RNO   *p*-value   FMO   RMO    *p*-value   FGO   RGO   *p*-value                                
  ------------------------ ----- ----- ----------- ----- ------ ----------- ----- ----- ----------- ------ ---- ----- ---- ----- ------
  Maximum width (mm)       56    5.7   49          5.3   ES     43          5.7   34    3.2         ES     51   6.8   49   5.4   0.19
  Width at point A (mm)    42    2.8   35          2.8   ES     39          2.4   32    4.7         ES     40   3.5   36   3     ES
  Maximum height (mm)      78    5.6   80          5.6   0.19   70          5.3   71    8.8         0.51   74   6.7   71   5.3   0.05
  Maximum thickness (mm)   47    4.2   34          4.9   ES     40          4.6   33    5.5         ES     41   6.8   38   5.2   0.07

###### 

3\. TRAK (cGy) per fraction at 1 m

         FNO    RNO     *p*-value   FMO     RMO   *p*-value   FGO     RGO     *p*-value                                        
  ------ ------ ------- ----------- ------- ----- ----------- ------- ------- ----------- ---- ------- ------- ------- ------- ------
  TRAK   0.59   0.002   0.439       0.066   ES    0.501       0.018   0.408   0.092       ES   0.602   0.088   0.509   0.243   0.09

###### 

4\. Treatment time (seconds)

         FNO    RNO   *p*-value   FMO   RMO   *p*-value   FGO   RGO   *p*-value                                
  ------ ------ ----- ----------- ----- ----- ----------- ----- ----- ----------- ---- ------ ----- ----- ---- ----
  Time   1143   184   729         91    ES    983         119   648   45          ES   1199   193   681   76   ES

FNO -- Fletcher style tandem ovoid applicator with no optimization, RNO -- ring applicator with no optimization, FMO -- Fletcher style tandem ovoid applicator with manual optimization, RMO -- ring applicator with manual optimization, FGO -- Fletcher style tandem ovoid applicator with graphical optimization, RGO -- ring applicator with graphical optimization

p \< 0.05 -- statistically significant, ES -- extremely statistically significant (p \< 0.0001), SD -- standard deviation

![**A)** Screenshots showing loading patterns, optimization techniques, isodose volumes, and cumulative and differential dose volume histogram generated after 'no optimization' using Fletcher tandem ovoid applicator. **B)** Although the loading patterns and optimization techniques are similar to Fletcher applicator as in [Figure 2A](#f0002){ref-type="fig"}, the 100% isodose is narrower and thinner, and dose delivered to contoured volumes are lower after using ring applicator](JCB-9-30804-g002){#f0002}

![Cont. **C)** Screenshots showing loading patterns, optimization techniques, isodose volumes, and cumulative and differential dose volume histogram generated after 'manual dwell weights/time' optimization using Fletcher tandem ovoid applicators. **D)** Although the loading patterns and optimization techniques are similar to Fletcher applicator as in [Figure 2C](#f0002a){ref-type="fig"}, the 100% isodose is narrower and thinner, and dose delivered to contoured volumes are lower after using ring applicator](JCB-9-30804-g002a){#f0002a}

![Cont. **E)** Screenshots showing loading patterns, optimization techniques, isodose volumes, and cumulative and differential dose volume histogram generated in after 'graphical optimization' using Fletcher tandem ovoid applicators. **F)** The loading patterns and optimization techniques after using ring applicator were similar to Fletcher applicator as in [Figure 2E](#f0002b){ref-type="fig"}. Since graphical optimization was done to achieve same dose-volume objectives, width and index thickness of 100% isodose is similar. Comparison of dose volume parameters, however, reveals ([Table 2](#t0002){ref-type="table"}) both adequate coverage of target and sparing of organs at risk is possible after graphical optimization with ring applicators in all high-dose-rate fractionation schedules](JCB-9-30804-g002b){#f0002b}

Dose to rectum {#sec3.13}
--------------

Since Fletcher applicator delivers dose both wider and thicker, D~0.1cc~, D~1cc~, D~2cc~, and V~20~ of rectum ([Table 2](#t0002){ref-type="table"}) and dose to rectal point ([Table 3](#t0003){ref-type="table"}) are significantly higher in all optimization techniques with Fletcher applicator. However, difference in recorded minimum, maximum, median, and average dose as well as V~50~ is significantly higher only if graphical optimization is not carried out.

Dose to sigmoid colon {#sec3.14}
---------------------

Although D~0.1cc~ and D~1cc~ are not significantly different between two applicators when no optimization is done, Fletcher applicator renders significantly higher D~2cc~, V~20~, V~50~, minimum, maximum, median, and average dose to sigmoid colon for all optimization techniques. However, doses are actually much lesser than that received by rectum as the sigmoid lies farther from the sources.

Dose to urinary bladder {#sec3.15}
-----------------------

D~0.1cc~, D~1cc~, D~2cc~ of urinary bladder are significantly higher with Fletcher applicator. As with rectum, difference in recorded minimum, maximum, median, and average dose is significantly higher only if graphical optimization is not done ([Table 2](#t0002){ref-type="table"}). Dose to bladder point is not significantly different (*p* \> 0.05).

Interestingly, when ring applicator along with graphical optimization is used, V~20~ in rectum and both V~20~ and V~50~ in urinary bladder, becomes statistically significantly higher. The probable explanation is that when higher isodose lines are dragged away from the contoured OAR in graphical optimization, the lower isodose regions come within automatically.

Which applicator/optimization is the best for satisfying both CTV and OAR dose volume recommendations at the same time? {#sec3.16}
-----------------------------------------------------------------------------------------------------------------------

[Figure 3](#f0003){ref-type="fig"} demonstrates that when treatment plans are normalized to point A, the use of ring applicator delivers lower dose to both CTV and OAR when compared to Fletcher applicator. Furthermore, the use of optimization using 'manual dwell weights/time', when compared to no optimization, reduces dose to most of the volumes. Although rectum and urinary bladder are well protected with use of ring applicator, the dose to 90% of CTV is inadequate unless graphical optimization is performed. On the other hand, Fletcher applicator provides adequate coverage to CTV, but also stretches very high dose to the organs at risk for all optimization processes.

![Horizontal bar diagram showing dose to ICRU points, median, average, and maximum dose, D90 & D100 for CTV and D1cc & D2cc for organs at risk in six plans from a patient](JCB-9-30804-g003){#f0003}

To investigate the best combination of applicator and optimization for different HDR fractionations, we calculated permissible dose per brachytherapy fraction to 2 cc of rectum, sigmoid colon, and urinary bladder to keep EQD~2~ to these volumes within recommended limits (see [Table 4A](#t0004a){ref-type="table"}). Permissible dose per fraction was then expressed as percentage of prescribed dose in different fractionations and compared to the results obtained from our study ([Table 4B](#t0004b){ref-type="table"}). Results show that both adequate coverage to CTV (D~90~ = 100% prescribed dose) and dose restriction to rectum (D~2cc~ \< 75 Gy EQD~2~) is possible after use of graphical optimization with Fletcher applicator, only in selected HDR dose-fractionation schedules (8.5 Gy for 2 fractions after external irradiation with EQD~2~ of 45-50 Gy, and 7 Gy for 3 fractions and 5.5 Gy for 5 fractions after EBRT with EQD~2~ of 45 Gy). When Fletcher applicator is used, urinary bladder always receive dose higher than recommended, even if graphical optimization is used with an intent not to compromise dose to CTV. Since sigmoid colon receives lesser dose, D~2cc~ is within permissible range in all optimization techniques, and both applicators for all HDR fractionations. On the other hand, ring applicator provides suboptimal D~90~ of CTV unless plan is graphically optimized. Thus, both adequate coverage of the target and sparing of the organs at risk simultaneously is possible in all fractionation schedules, only after graphical optimization with ring applicators. Judicious activation of dwell positions and graphical optimization after the use of Fletcher applicator, however, may generate desired dose volume parameters for all volumes of interest in other HDR fractionation schedules also.


###### 

A. Calculated permissible dose per fraction to 2 cc rectum and urinary bladder in different dose-fractionations of HDR brachytherapy, considering total EQD~2~ 75 Gy for 2 cc rectum and sigmoid colon and 90 Gy for 2 cc urinary bladder (α/β = 3 Gy), and assuming full dose of external beam therapy in the volume of interest

  Number of BT fractions (a)   CTV       Rectum   Sigmoid colon   Urinary bladder                                                                                    
  ---------------------------- --------- -------- --------------- ----------------- --------- ----------- ------------ --------- ----------- ------------- --------- -------------
  2                            8.5 Gy    50 Gy    76.2 Gy         25 Gy             654 cGy   76.9% (f)   25 Gy        654 cGy   76.9% (r)   40 Gy         861 cGy   101.3% (dd)
  45 Gy                        71.2 Gy   30 Gy    729 cGy         85.8% (g)         30 Gy     729 cGy     85.8% (s)    45 Gy     921 cGy     108.4% (ee)             
  3                            7 Gy      50 Gy    79.8 Gy         25 Gy             512 cGy   73.1% (h)   25 Gy        512 cGy   73.1% (t)   40 Gy         680 cGy   97.1% (ff)
  45 Gy                        74.8 Gy   30 Gy    572 cGy         81.7% (i)         30 Gy     572 cGy     81.7% (u)    45 Gy     729 cGy     104.1% (gg)             
  3                            8 Gy      50 Gy    86 Gy           25 Gy             512 cGy   64% (j)     25 Gy        512 cGy   64% (v)     40 Gy         680 cGy   85% (hh)
  45 Gy                        81 Gy     30 Gy    572 cGy         71.5% (k)         30 Gy     572 cGy     71.5% (w)    45 Gy     729 cGy     91.1% (ii)              
  4                            7 Gy      50 Gy    89.7 Gy         25 Gy             428 cGy   61.1% (l)   25 Gy        428 cGy   61.1% (x)   40 Gy         572 cGy   81.7% (jj)
  45 Gy                        84.7 Gy   30 Gy    480 cGy         68.5% (m)         30 Gy     480 cGy     68.5% (y)    45 Gy     614 cGy     87.7% (kk)              
  5                            5.5 Gy    50 Gy    80.5 Gy         25 Gy             372 cGy   67.6% (n)   25 Gy        372 cGy   67.6% (z)   40 Gy         500 cGy   90.9% (ll)
  45 Gy                        85.5 Gy   30 Gy    417 cGy         75.8% (o)         30 Gy     417 cGy     75.8% (aa)   45 Gy     537 cGy     97.6% (mm)              

HDR -- high-dose-rate, BT -- brachytherapy, EBRT -- external beam radiotherapy, PD -- prescribed dose to point A or 90% volume (D~90~), EQD~2~ -- 2 Gy equivalent dose

###### 

B. Percentage of prescribed dose received (median values) in six plans by 2 cc rectum, sigmoid colon and urinary bladder in our study and commonly used HDR dose fractionations that will permit the same percentage dose to 2 cc OAR as shown in [Table 4A](#t0004a){ref-type="table"}

  Applicator and optimization used   CTV      Rectum     Sigmoid colon                                                       Urinary bladder                    
  ---------------------------------- -------- ---------- ------------------------------------------------------------------- ----------------- ----- ---------- ------
  FNO                                145%     106.625%   None                                                                44.5%             All   134.625%   None
  RNO                                89%      52.625%    All                                                                 34.6%             All   67.375%    All
  FMO                                123%     97.75%     None                                                                42.6%             All   113.875%   None
  RMO                                80.75%   44.75%     All                                                                 25.8%             All   68.625%    All
  FGO                                100.8%   74.25%     f, g, i, o (from [Table 4A](#t0004a){ref-type="table"}, column e)   40.1%             All   115.125%   None
  RGO                                100.2%   59%        All                                                                 29.3%             All   75.875%    All

FNO -- Fletcher style tandem ovoid applicator with no optimization, RNO -- ring applicator with no optimization, FMO -- Fletcher style tandem ovoid applicator with manual optimization, RMO -- ring applicator with manual optimization, FGO -- Fletcher style tandem ovoid applicator with graphical optimization, RGO -- ring applicator with graphical optimization, PD -- prescribed dose

Conclusions {#sec4}
===========

The choice of brachytherapy applicators depends on their availability, patient's anatomy and the decision of the radiation oncologist. The optimization technique to be adopted however depends on medical physicist's preference and the readiness to adhere to dose-volume objectives. In this study, the combination of graphical optimization and the application of ring applicators easily engendered realization of dose-volume objectives in all HDR dose-fractionation schedules. On the other hand, Fletcher style tandem-ovoid applicator generates very high dose to 2 cc volumes of OAR in addition to high-dose to CTVs. Further studies with these two applicator systems should be conducted with larger number of patients. These may include optimization techniques like IPSA and HIPO. Rectal and bladder wall contouring may be attempted if MRI is used for imaging.
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